

## Valeant Pharmaceuticals Announces 2014 Annual Meeting Results

May 21, 2014

LAVAL, Quebec, May 21, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of ten directors nominated at its 2014 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below:

<b>Name</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Ronald H. Farmer	251,288,239	908,255	21,179,009
Colleen A. Goggins	251,712,817	483,677	21,179,009
Robert A. Ingram	249,639,221	2,557,273	21,179,009
Anders Lonner	251,650,643	545,851	21,179,009
Theo Melas-Kyriazi	251,423,599	772,895	21,179,009
J. Michael Pearson	246,575,385	5,621,109	21,179,009
Robert N. Power	250,186,656	2,009,838	21,179,009
Norma A. Provencio	251,604,073	592,421	21,179,009
Howard B. Schiller	238,521,290	13,675,204	21,179,009
Katharine B. Stevenson	250,315,363	1,881,131	21,179,009

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement; appointed PricewaterhouseCoopers LLP (United States) as the Company's independent registered public accounting firm until the close of the Company's 2015 annual meeting of shareholders; and approved the 2014 Omnibus Incentive Plan and the ratification and approval of the grants of 320,033 share units and 180,000 options which were made subject to the shareholder approval of the 2014 Plan.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be

made available on the Company's web site,  
[www.valeant.com](http://www.valeant.com)

### About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at [www.valeant.com](http://www.valeant.com)

### Contact Information:

Laurie W. Little  
949-461-6002  
[laurie.little@valeant.com](mailto:laurie.little@valeant.com)

SOURCE Valeant Pharmaceuticals International, Inc.



### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)  
877-281-6642  
514-856-3855 (Canada)

### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)  
908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.  
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**

